Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Withdrawn No phase listed Observational

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

NCT00977158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Throat Swab
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
1 Day to 3 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

NCT04684641
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Standard Dose YPT-01, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 13, 2026, 9:22 PM EDT
Active, not recruiting No phase listed Observational

Gene Modifiers of Cystic Fibrosis Lung Disease

NCT00037765
View directory record Official record
Conditions
Cystic Fibrosis, Lung Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

NCT02566044
View directory record Official record
Conditions
Pulmonary Cystic Fibrosis
Interventions
Placebo, QBW276
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional

Growth Hormone Use in Cystic Fibrosis - a Multicenter Study

NCT00005112
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Human recombinant growth hormone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BioEnergetics and Metabolomics in Cystic Fibrosis

NCT02225899
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT03125395
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Withdrawn Not applicable Interventional

Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients

NCT01229553
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
decolonization
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
2 Months to 23 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Withdrawn No phase listed Observational

An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients

NCT00765401
View directory record Official record
Conditions
Cystic Fibrosis, Abdominal Pain, Helicobacter Pylori Infection
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Results available

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis

NCT04118010
View directory record Official record
Conditions
Cystic Fibrosis, Dysbiosis
Interventions
Vitamin D3, Placebo vitamin D3, Inulin, Placebo Inulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 13, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

NCT02951195
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-152, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational

Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium

NCT02288429
View directory record Official record
Conditions
Colistin
Interventions
colistimethate sodium
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Aurora, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational

Cough-Generated Aerosols of NTM in Cystic Fibrosis

NCT01815866
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CF with culturable NTM
Procedure
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

NCT05982795
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 and Rifampin in Healthy Male Subjects

NCT01018368
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Rifampin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Oct 13, 2026, 9:22 PM EDT
Recruiting Phase 2Phase 3 Interventional

Maralixibat in Patients With Cystic Fibrosis and Constipation

NCT06413368
View directory record Official record
Conditions
Constipation Chronic Idiopathic, Cystic Fibrosis
Interventions
Maralixibat 9.5 MG/ML [Livmarli]
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
48
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

NCT05719311
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
adrulipase
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Orlando, Florida • Northfield, Illinois • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

NCT03181932
View directory record Official record
Conditions
MRSA, Cystic Fibrosis
Interventions
Vancomycin inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
6 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
69
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 13, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03525444
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 13, 2026, 9:22 PM EDT
Completed No phase listed Observational

Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF

NCT02109822
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
12 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 13, 2026, 9:22 PM EDT